These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 20494948)

  • 21. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
    Vaidyanathan G; Groman A; Wilding G; Fakih MG
    Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
    Zhao Z; Pelletier E; Barber B; Bhosle M; Wang S; Gao S; Klingman D
    Curr Med Res Opin; 2012 Feb; 28(2):221-9. PubMed ID: 22171947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
    Afonso S; Viani G; Afonso V; Stefano E; Afonso S
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
    Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
    Usui K; Katou Y; Furushima K; Tanaka Y; Tanai C; Ishihara T
    Jpn J Clin Oncol; 2011 Apr; 41(4):498-502. PubMed ID: 21303791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
    Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
    Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
    Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
    Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 32. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients.
    Ferroni P; Martini F; Portarena I; Massimiani G; Riondino S; La Farina F; Mariotti S; Guadagni F; Roselli M
    Clin Lung Cancer; 2012 Nov; 13(6):482-7. PubMed ID: 22591606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
    J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
    Tsutsumi S; Fukasawa T; Fujii T; Tabe Y; Kigure W; Asao T; Kuwano H
    Hepatogastroenterology; 2012 Jun; 59(116):1079-80. PubMed ID: 22580658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
    Schwartzman AD; Sethi R; Smith R
    Clin Colorectal Cancer; 2013 Jun; 12(2):136-9. PubMed ID: 23098664
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
    Suenaga M; Mizunuma N; Kobayashi K; Shinozaki E; Matsusaka S; Chin K; Kuboki Y; Ichimura T; Ozaka M; Ogura M; Fujiwara Y; Matsueda K; Konishi F; Hatake K
    Med Oncol; 2010 Sep; 27(3):807-14. PubMed ID: 19697164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
    Lièvre A; Samalin E; Mitry E; Assenat E; Boyer-Gestin C; Lepère C; Bachet JB; Portales F; Vaillant JN; Ychou M; Rougier P
    BMC Cancer; 2009 Sep; 9():347. PubMed ID: 19785749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent disease four years after surgery and adjuvant chemotherapy.
    Pozzo C; Barone C
    Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.
    Xie S; Han G; Fan Z; He L; Xu W; Qin Z
    Med Oncol; 2014 Jul; 31(7):35. PubMed ID: 24915899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.